Sprint Bioscience AB logo

Sprint Bioscience AB (SPRINT)

Market Closed
10 Aug, 15:25
XSTO XSTO
kr
3. 44
-0.06
-1.7143%
kr
392.52M Market Cap
- P/E Ratio
- Div Yield
91,997 Volume
0 Eps
kr 3.5
Previous Close
Add Transaction
Day Range
3.4 3.59
Year Range
0.4 4.21
Want to track SPRINT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SPRINT closed today lower at kr3.44, a decrease of -1.7143% from yesterday's close, completing a monthly increase of 11.6883% or kr0.36. Over the past 12 months, SPRINT stock gained 138.8889%.
SPRINT is not paying dividends to its shareholders.
The last earnings report, released on May 25, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.3309%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XSTO (SEK).

SPRINT Chart

People also search for

Pricer AB
kr -
-
BioArctic AB
kr -
-
DIAMYD MEDICAL AB
kr -
-
Bactiguard Holding AB
kr -
-
Genovis AB
kr 19.7
-0.5051%

Sprint Bioscience AB (SPRINT) FAQ

What is the stock price today?

The current price is kr3.44.

On which exchange is it traded?

Sprint Bioscience AB is listed on XSTO.

What is its stock symbol?

The ticker symbol is SPRINT.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 392.52M.

Has Sprint Bioscience AB ever had a stock split?

No, there has never been a stock split.

Sprint Bioscience AB Profile

Biotechnology Industry
Healthcare Sector
Mr. Johan Emilsson CEO
XSTO Exchange
SE0006343745 ISIN
SE Country
30 Employees
- Last Dividend
3 Apr 2025 Last Split
- IPO Date

Overview

Sprint Bioscience AB (publ) is a distinguished pharmaceutical company headquartered in Huddinge, Sweden, dedicated to the development of innovative pharmaceutical products primarily focused on the treatment of cancer. Since its inception in 2009, the company has been at the forefront of research and development in the oncology sector, leveraging state-of-the-art technologies and scientific approaches to address some of the most challenging aspects of cancer treatment. Sprint Bioscience's commitment to improving patient outcomes through the development of novel therapeutics makes it a key player in the pharmaceutical landscape of Sweden and the global market.

Products and Services

  • VPS34

    Sprint Bioscience's VPS34 is a pioneering drug candidate designed for the treatment of various types of cancer. It operates by utilizing immunotherapies, a cutting-edge approach that stimulates the body's immune system to target and destroy cancer cells effectively. This innovative therapy represents the company's commitment to providing alternative cancer treatment options that could potentially offer better outcomes for patients suffering from this devastating disease.

  • PETRA01

    PETRA01 is another significant drug candidate developed by Sprint Bioscience, aimed at the treatment of cancer. While specific details of its mechanism of action and target cancers are not provided, this development underscores the company's ongoing efforts to expand its portfolio of cancer therapies. By focusing on novel targets and leveraging unique therapeutic strategies, Sprint Bioscience aims to make substantial contributions to the field of oncology.

  • Research in Tumor Metabolism, NASH, and Diabetes

    Apart from its primary focus on cancer therapeutics, Sprint Bioscience also engages in research targeting tumor metabolism, non-alcoholic steatohepatitis (NASH), and diabetes. This research is indicative of the company's broader interest in addressing various significant health issues through the discovery and development of new pharmaceutical products. By exploring treatments in these areas, Sprint Bioscience is working towards providing innovative solutions that could improve the quality of life for patients suffering from these conditions.

Contact Information

Address: Novum, Huddinge, Sweden, 141 57
Phone: 46 84 11 44 55